2/4/2010 6:00 AM EST
-
Orexo
Uppsala, February 4, 2010 – Orexo AB (STO: ORX) today confirms that its partner, ProStrakan Group plc (LSE: PSK) has announced that the New Drug Submission made by their Canadian partner, Paladin Labs Inc., for AbstralTM has been accepted for review by Health Canada, the Canadian Government Department with responsibility for public health.
AbstralTM, developed by Orexo AB is a new, rapidly disintegrating,...